The Faster Clinical Trials Act would create an FDA Center for Clinical Trial Innovation and aims to cut trial costs and enrollment time by at least 30%.
|Articles|September 1, 2011
- Applied Clinical Trials-09-01-2011
- Volume 20
- Issue 9
Applied Clinical Trials Digital Edition - September 2011
SUBJECT RECRUITMENT : Integrated Team - Sponsors, CROs, and Sites Patient Tracking Services Can Help Reduce Lost to Follow-Up TRIAL DESIGN : Pediatric Trials - Errors in Informed Consent Also in this issue : Common Rule Revision, EU?s Health Policy and Clinical Trials, CROs Going Private, Research Clusters
Advertisement
Articles in this issue
about 15 years ago
Most Protocols Require Multiple Amendmentsabout 15 years ago
Recruitment Rolesabout 15 years ago
Uniformity Sought for Research Standardsabout 15 years ago
EMA Commits to London for a Quarter Centuryabout 15 years ago
Cell Phone Key to REMOTE Data Collectionabout 15 years ago
Clusters' Last Stand?about 15 years ago
Lost to Follow-Up Survey Resultsabout 15 years ago
Business and News Update September 2011about 15 years ago
Pharma Companies Lose Facebook Privilegesabout 15 years ago
Sneak Peak at FDA GuidanceAdvertisement
Related to this article
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
In today’s ACT Brief, we examine how sites can avoid both fear-driven and overly aggressive AI adoption, why community-based research needs sustained financial investment, and why patient access matters more than organizational size.
Pacing obesity trial enrollment, anchoring eligibility to stable real-world therapies, and building site and physician relationships improve retention and data quality more than aggressive recruitment or restrictive exclusion criteria do.
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Syneos Health and Optum outline a joint model for trial planning, recruitment and site access, with no financial terms or timelines disclosed.
AstraZeneca and Oracle Outline AI Collaboration for Clinical Trial Recruitment and Safety Monitoring
What sponsors and sites should know about the AstraZeneca-Oracle AI collaboration on trial recruitment, safety monitoring and data governance.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
2
Where AI Governance in Clinical Development Falls Short
3
Building Standardized Evidence for eSource-Enabled Clinical Trials: Multi-Site Validation of a Clinical Research Coordinator Satisfaction Methodology
4
Syneos Health, Optum Partner on Adaptive Clinical Development Model
5